Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

NIS793/Placebo + Gemcitabine and Nab-paclitaxel for 1st line treatment in pancreatic cancer

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma

Disease Types: Pancreatic

Available at: BlacksburgRoanokeSalemWythevilleAlleghany

A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma

For More Information:

https://clinicaltrials.gov/ct2/show/NCT04935359?term=A+randomized%2C+double-blind%2C+phase+III+study+comparing+NIS793+in+pancreatic+cancer&draw=1&rank=1